Evidence map›Paper›PMID 41085570›Full record

ArticleLung2025

Fatty Acids Dysregulation Correlates with Lung Function in Idiopathic Pulmonary Fibrosis.

Filippo Scialò, Raffaella Pagliaro, Monica Gelzo, Maria Gabriella Matera, Vito D'Agnano, Stefano Sanduzzi Zamparelli, Giuseppe Castaldo, Mario Cazzola, Andrea Bianco, Fabio Perrotta

Abstract read
In one paragraph

Article in Lung, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Article
  2. Review
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Filippo ScialòDepartment of Molecular Medicine and Medical Biotechnologies, University of Naples "Federico II", Naples, Italy.
Raffaella PagliaroDepartment of Translational Medical Sciences, University of Campania 'L. Vanvitelli', Naples, Italy.
Monica GelzoDepartment of Molecular Medicine and Medical Biotechnologies, University of Naples "Federico II", Naples, Italy.
Maria Gabriella MateraUnit of Pharmacology, Department of Experimental Medicine, University of Campania 'L. Vanvitelli', Naples, Italy.
Vito D'AgnanoDepartment of Translational Medical Sciences, University of Campania 'L. Vanvitelli', Naples, Italy.
Stefano Sanduzzi ZamparelliDivision of Pneumology and Semi-Intensive Respiratory Therapy, A. Cardarelli Hospital, 80131, Naples, Italy.
Giuseppe CastaldoDepartment of Molecular Medicine and Medical Biotechnologies, University of Naples "Federico II", Naples, Italy.
Mario CazzolaUnit of Respiratory Medicine, Department of Experimental Medicine, University of Rome "Tor Vergata", Rome, Italy. mario.cazzola@uniroma2.it.
Andrea BiancoDepartment of Translational Medical Sciences, University of Campania 'L. Vanvitelli', Naples, Italy. andrea.bianco@unicampania.it.
Fabio PerrottaDepartment of Translational Medical Sciences, University of Campania 'L. Vanvitelli', Naples, Italy.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundIdiopathic pulmonary fibrosis (IPF) is a progressive lung disease with a poor survival rate and undefined molecular mechanisms. The identification of reliable biomarkers to help early diagnosis and predict disease progression is crucial for improving patient life. Although many biomarkers have been proposed, there is no consensus on reliable markers for IPF. Alterations in fatty acid (FA) metabolism have drawn increasing attention in the IPF pathogenesis.

methodsThis single-center, prospective, cross-sectional study enrolled 35 IPF patients and 24 control participants. Demographic, clinical, and pulmonary function data were collected. FA profiles were compared between the two groups, with statistical analyses including chi-square tests, ANOVA, Spearman's rank correlation, and ROC curve analysis.

resultsWe found significant differences in serum FA levels between IPF patients and controls. Cis-Palmitoleic acid (26.4 mg/L vs 22.1 mg/L; p = 0.04), oleic acid (457.6 mg/L vs 376.4 mg/L, p = 0.04), and elaidic acid (33.7 mg/dL vs 28.2 mg/L, p = 0.02) were increased in IPF patients, while arachidonic acid (79.7 mg/dL vs 97.9 mg/L, p = 0.01) levels were significantly lower compared to the control group. Spearman's correlation analysis revealed positive correlations between these fatty acids. Notably, arachidonic acid levels showed a positive correlation with FEV1% (r = 0.348; p = 0.043) and FVC% (r = 0.431; p = 0.01), although ROC curve analysis indicated that this did not demonstrate strong diagnostic potential for IPF.

conclusionIn this study, we identified a dysregulation of cis-palmitoleic acid, oleic acid, elaidic acid, and arachidonic acid in IPF patients, indicating alterations in lipid metabolism and inflammatory pathways. Additionally, while arachidonic acid levels correlate with lung function, its diagnostic potential remains uncertain and warrants further evaluation in a larger patient population.

Indexed as

Fatty AcidsIdiopathic Pulmonary FibrosisLungAgedArachidonic AcidBiomarkersCase-Control StudiesCross-Sectional StudiesFatty Acids, MonounsaturatedFemaleForced Expiratory VolumeHumansMaleMiddle AgedOleic AcidProspective StudiesArachidonic AcidBiomarkersFatty AcidsFatty Acids, MonounsaturatedOleic Acidpalmitoleic acidArachidonic acidCis palmitoleic acidFatty acidsIdiopathic pulmonary fibrosisOleic acid

Identifiers

PMID41085570
PMCPMC12521298

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.